Positive data reported in phase II ELEKTRA study of soticlestat in children with Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS)

Study of this highly selective, oral inhibitor of the enzyme cholesterol 24-hydroxylase reached its primary endpoint with a 27.8% median reduction from baseline in convulsive seizure and drop seizure frequency, compared to a 3.1% median increase in patients on placebo.


Biospace Inc.